| Application no. and date | 15724351.0 (espacenet) (Federated) (European Patent Register), 20150505 | | Patent/reg. no. and date | DK/EP 3140303, 20180328 | | Publication date | 20170315 | | Priority no. and date | US 201461990232 P, 20140508 | | EP pub. no. and date |
EP 3140303 20170315 | | Effective date | | | Applicant/owner | Astrazeneca AB, 151 85 Södertälje, SE | | Applicant ref. no. | AST 200222-EP-EPT | | Inventor | BARLAAM, Bernard Christophe, AstraZeneca Darwin Building
Cambridge Science Park
Milton Road
Cambridge, CB4 OWG, GB,
PIKE, Kurt Gordon, AstraZeneca Darwin Building
Cambridge Science Park
Milton Road
Cambridge CB4 OWG, GB | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB
, GB | | Opponent | | | IPC Class | A61K 31/437 (2006.01) , A61P 35/00 (2006.01) , C07D 471/04 (2006.01) | | Title | IMIDAZO[4,5-C]QUINOLIN-2-ONFORBINDELSER OG ANVENDELSE DERAF VED BEHANDLING AF CANCER | | Int. application no. | GB2015051312 | | Int. publication no. | WO2015170081 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
